Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM. (PubMed, Crit Rev Oncol Hematol) - Sep 27, 2026 - "In SIMPLIFY-1, momelotinib demonstrated non-inferiority to ruxolitinib in terms of spleen volume reduction (SVR35 26.5% vs 29.0%) and did not evaluated quality of life as a prespecified outcome, resulting in an ESMO-MCBS:H score indicating no evaluable benefit (NEB). In contrast, in MOMENTUM, conducted in symptomatic, anemic patients previously treated with JAK inhibitors, momelotinib was superior to danazol for MFSAF total symptom score response (≥50% reduction from baseline 25% vs 9%)...However, superiority over other improved JAK inhibitors has not been demonstrated in the pivotal phase 3 trials evaluated. Future trials incorporating anemia-focused primary endpoints and biomarker stratification are warranted to better define its role in myelofibrosis management."
Journal • Review • Chronic Eosinophilic Leukemia • Hematological Disorders • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • ACVR1 • JAK1 • JAK2
|
|
B E Oortgiesen; E Ammatuna; M Hoogendoorn; R van Rijn; S A L Wever; S K Klein
|